Nuohexiziyuan (688315): Q3 operations are stable, with continued expansion of overseas localization.
Nuohetoyuan released the third quarter report of 2024. In 2024 Q1-Q3, achieved revenue of 1.519 billion yuan, a year-on-year increase of 6.31%; net income attributable to parent company of 0.134 billion yuan, a year-on-year increase of 7.33%; after non-recurring items attributable to parent company.
Norhizhiyuan (688315.SH): No share repurchase was conducted in October 2024.
On November 3, Gelonhui announced that in October 2024, Nuoheto Source (688315.SH) did not repurchase shares. As of October 31, 2024, the company has repurchased a total of 11,141,468 shares through the Shanghai Stock Exchange trading system by means of centralized bidding trading, accounting for 2.68% of the total share capital. The highest repurchase price was 15.86 yuan/share, the lowest price was 9.69 yuan/share, and the total amount of funds paid was RMB 144.1475 million (excluding stamp duty, transaction commission and other trading fees).
Nuoheto Zhichuan (688315): Profit growth rate returns to normal, full-year profit growth is expected to accelerate.
Investment Highlights: The company disclosed its 2024 third-quarter report, with revenue of 1.519 billion yuan in the first three quarters, a year-on-year increase of 6.3%; net income attributable to the parent company of 0.134 billion yuan, a year-on-year increase of 7.3%. Among them, Q3 revenue was 0.523 billion yuan, the same.
The smart automation continues to upgrade, and the global localization is steadily advancing at Nuohesizy (688315).
The core view of the company's performance in 2024Q1-3 meets expectations, returning to a healthy growth track since 24 years. The small flexible asia vets delivery system Falcon III is launched, intelligent automation continues to upgrade, and the new system has already been
Beijing Novo Zhiyuan Technology Co., Ltd. Report for the third quarter of 2024
Nohesizhiyuan (688315.SH): The net income in the first three quarters was 0.134 billion yuan, a year-on-year increase of 7.33%.
GeLongHui on October 24th, Nuohe Zhiyuan (688315.SH) released its third-quarter report, with revenue of 1.519 billion yuan, a year-on-year growth of 6.30%, net income of 0.134 billion yuan, a year-on-year growth of 7.33%, non-GAAP net income of 0.11 billion yuan, a year-on-year growth of 7.26%, and a basic earnings per share of 0.33 yuan.
Nuohenzhizyuan (688315.SH) released its performance for the first three quarters, with a net income of 0.134 billion yuan, a year-on-year increase of 7.33%.
Nuohexi (688315.SH) disclosed the third quarter report of 2024, achieving revenue of 15...
Nuohetong Source (688315.SH) suffered shareholding from shareholders Zhiyuanhe Valley and Nuohethe Valley, with a cumulative reduction of 1.91% of shares.
Nuohetoo Source (688315.SH) announced that shareholders Zhiyuanhegu and Nuohetoohegu have cumulatively reduced their shareholding in the company by 79...
Noah Zhixuan (688315.SH): The company did not repurchase shares in August.
On August 31, 2024, Nuohuzhiyuan (688315.SH) announced that the company did not repurchase shares in August 2024. As of August 31, 2024, the company has repurchased a total of 11,141,468 shares of the company through the Shanghai Stock Exchange trading system through centralized bidding trading method, accounting for 2.68% of the company's total share capital. The highest price of repurchase was 15.86 CNY/share and the lowest price was 9.69 CNY/share. The total amount paid was 144.1475 million CNY (excluding stamp duty, transaction fees, and other trading expenses).
NUOHEZHIYUAN (688315): Balanced development at home and abroad, gross margin steadily increasing.
In 2024 Q2, the company's revenue was 0.528 billion yuan (+7.94% YoY) with a net income of 0.051 billion yuan (-3.66% YoY) and a non-recurring net income of 0.045 billion yuan (+16%).
Nuohezhichuan (688315): Returning to a healthy growth track with continued global layout implementation.
The company's revenue achieved stable growth in the first half of 2024, with double-digit growth on the non-GAAP profit side. Performance met expectations, with growth in both domestic and overseas markets, and stable profitability. The company has established a globally standardized management system and quality management.
Nuohe Zhiyuan (688315): Performance stabilizes and recovers, global localization layout continues to be promoted.
Event: The company has released its 2024 semi-annual report, with revenue of 0.997 billion yuan (+7.18%) and net income attributable to shareholders of 0.078 billion yuan (+3.86%) for the period of January to June 2024, and non-GAAP net income of 0.066 billion yuan. (
Nuohe Zhiyuan (688315): steady performance growth, and continuous optimization of infrastructure.
Event: On August 14, 2024, the company released its mid-year report for 2024. In the first half of 2024, the company achieved a revenue of 0.997 billion yuan, a year-on-year increase of 7.18%; achieved a net income attributable to the parent of 0.078 billion yuan.
Nuohe Zhuyuan (688315): Business is steadily recovering, and global layout continues to advance.
Key points: Nooherb released its mid-term performance for 2024. The company achieved a revenue of 0.997 billion yuan (+7.18%) and a net profit attributable to the parent company of 77.93 million yuan (+3.86%). The non-net profit attributable to parent company was 659.
Peking Nuohozhiyuan Technology Co., Ltd.'s semi-annual report of 2024.
Summary of the 2024 interim report of Peking Nuohexiziyuan Technology Co., Ltd.
Does a single product weaken core competitiveness? Noah's source is lacking in growth momentum.
Compared to the first half of 2023, Nuohesizyuan's revenue growth rate decreased by 2.26 percentage points this year, while net income growth rate plummeted by 28.48 percentage points. Nuohesizyuan revealed that with the rapid development of Qualcomm's high-throughput sequencing technology, competition for mature products and services in China will become increasingly fierce, and future product prices may continue to decline.
Nuohe Zhiyuan (688315.SH): net income of 77.9269 million yuan in the first half of the year, a year-on-year increase of 3.86%.
On August 14th, Gelonhui reported the 2024 semi-annual report for Nuohetoyuan (688315.SH), which achieved revenue of 0.997 billion yuan during the reporting period, a year-on-year increase of 7.18%; net profit attributable to shareholders of listed companies was 77.9269 million yuan, a year-on-year increase of 3.86%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 65.9107 million yuan, a year-on-year increase of 12.92%; and basic earnings per share were 0.19 yuan. During the reporting period, the company's operating income was 0.997 billion yuan, a year-on-year increase of 7.18%, mainly due to mainland China, Hong Kong, Macao, Taiwan, and overseas areas.
Nuohe Zhiyuan (688315): Steady recovery in China, continuing overseas expansion.
Investment Highlights: On August 14, 2024, the company released its half-yearly report for 2024, with revenue of 0.997 billion yuan, a year-on-year increase of 7.2%, including 0.528 billion yuan in Q2 revenue, a year-on-year increase of 7.
Noah Biologicals (688315.SH): has accumulated repurchased 2.68% of shares.
On August 2nd, Gelun Hui announced that up to July 31st, 2024, the company has repurchased a total of 11,141,468 shares of the company through the Shanghai Stock Exchange trading system with a centralized bidding trading method, accounting for 2.68% of the total share capital. The highest repurchase price was 15.86 yuan/share, the lowest price was 9.69 yuan/share, and the total amount of funds paid was 144.1475 million yuan (excluding stamp duty, transaction fees and other trading expenses).